Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 4/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.33 |
| ▸ | RAPGEF3 | O95398 | 6/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.31 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10150558 | 0.81 | — | — | |
| SCHEMBL17826380 | 0.75 | PDE4A (0.40) | KMT2AMEN1ALDH1A1PDE4APDE4B | |
| SCHEMBL18720669 | 0.75 | RXFP1 (0.41) | KMT2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL16158835 | 0.74 | RXFP1 (0.33) | PDE4APDE4BPDE4CPDE4DRXFP1 | |
| SCHEMBL16158834 | 0.72 | KMT2A (0.51) | KMT2AMEN1ALDH1A1PDE4APDE4B | |
| SCHEMBL18720698 | 0.71 | RXFP1 (0.37) | KMT2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL17826381 | 0.70 | STING1 (0.67) | STING1 | |
| SCHEMBL18720658 | 0.67 | RXFP1 (0.36) | PDE4APDE4BPDE4CPDE4DRXFP1 | |
| SCHEMBL16158820 | 0.67 | STING1 (0.54) | STING1 | |
| SCHEMBL15459909 | 0.64 | LMNA (0.42) | KMT2AMEN1ALDH1A1THRBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365605-B2 | Cyclic nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140303108-A1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2014-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303108-A1 | CYCLIC NUCLEOTIDE ANALOGS | NT5C2, NTPCR, PNP | KMT2A 3789/4885MEN1 1451/4885ALDH1A1 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.